Johnson & Johnson (NYSE:JNJ) Shares Sold by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,516 shares of the company’s stock after selling 350 shares during the quarter. EagleClaw Capital Managment LLC’s holdings in Johnson & Johnson were worth $2,899,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. DORCHESTER WEALTH MANAGEMENT Co boosted its position in Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after acquiring an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P boosted its position in Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after acquiring an additional 82,429 shares during the last quarter. AMI Investment Management Inc. boosted its position in Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after acquiring an additional 1,475 shares during the last quarter. Equitable Holdings Inc. boosted its position in Johnson & Johnson by 4.9% during the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after acquiring an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd boosted its position in Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after acquiring an additional 20,528 shares during the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $149.91 on Tuesday. The company has a market cap of $360.88 billion, a P/E ratio of 11.13, a PEG ratio of 3.00 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $181.04. The firm’s 50 day moving average price is $154.52 and its 200 day moving average price is $160.29.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.52 by $0.14. The company had revenue of $21.35 billion during the quarter, compared to the consensus estimate of $21 billion. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. On average, research analysts forecast that Johnson & Johnson will post 10.1 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st will be issued a $1.19 dividend. The ex-dividend date of this dividend is Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio is presently 35.34%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Wells Fargo & Company decreased their target price on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a report on Thursday, August 31st. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday. Atlantic Securities boosted their target price on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Royal Bank of Canada assumed coverage on shares of Johnson & Johnson in a report on Wednesday, October 4th. They issued an “outperform” rating and a $178.00 target price on the stock. Finally, Raymond James decreased their target price on shares of Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, October 18th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $169.19.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.